Direct percutaneous mitral annuloplasty offers a feasible, less invasive approach for treating functional mitral regurgitation in high-surgical-risk patients by addressing annular dilatation.
Answers are grounded in this paper and cite their sources.
Supports safety of direct percutaneous mitral annuloplasty in high-risk MR; leaves open efficacy confirmation in randomized trials.
Mitral regurgitation (MR) is a frequent valvular disease among patients deemed too high risk for surgery. Echocardiography along with CT is the primary diagnostic tool for MR and offers a comprehensive 3D assessment in patient selection and screening for the optimal treatment method. The direct percutaneous mitral annuloplasty addresses the underlying mechanisms of functional MR with a less invasive, catheter-based approach. The here-described techniques proved a sufficient safety profile, delivered significant MR reduction in most of the cases, and were associated with a notable improvement of symptoms. Although long-term outcome assessment is needed to support these early reports, the percutaneous mitral annuloplasty is likely to set a new standard of treatment in the forthcoming future.
No takes yet. Share an insight, caveat, or question.
Gąsior et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: